Lorid

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lorid

What is Lorid?

Lorid is a pharmaceutical medication containing the active ingredient loratadine. It belongs to a class of drugs known as second-generation antihistamines. These medications are primarily used to manage symptoms associated with allergic reactions.

Mechanism of Action

The medication works by blocking the action of histamine, a natural substance in the body that is released during an allergic response. Histamine attaches to specific receptors (H1 receptors) on cells, leading to common allergy symptoms. By selectively inhibiting these receptors, Lorid helps reduce the physiological response to allergens without significantly affecting the central nervous system.

Therapeutic Use

Lorid is typically utilized to provide relief from symptoms triggered by seasonal and perennial allergies. It is commonly used for:

  • Allergic Rhinitis: Reducing symptoms such as sneezing, runny or itchy nose, and nasal congestion.
  • Allergic Conjunctivitis: Alleviating itchy, watery, or red eyes.
  • Urticaria: Managing chronic hives and skin-related allergic reactions, including itching and rashes.

General Characteristics

As a second-generation antihistamine, Lorid is designed to be non-sedating for the majority of users. Unlike earlier antihistamines, it does not readily cross the blood-brain barrier, which minimizes the likelihood of drowsiness or impaired cognitive function when taken at standard therapeutic levels. It is formulated to provide long-acting relief, generally maintaining its effect for a full day.

Regulatory References

  1. Loratadine - LiverTox - NCBI Bookshelf
  2. MedlinePlus Drug Information

What side effects are possible with Lorid?

Possible Side Effects and Safety Information

The safety profile of Lorid (loratadine) is officially documented according to standardized regulatory categories defined by government health authorities. Adverse reactions are classified by how frequently they are reported in clinical trials and post-marketing surveillance.

Frequency-Classified Adverse Reactions

The most Common adverse reactions reported in adults and adolescents include headache, somnolence (drowsiness), increased appetite, and insomnia (difficulty sleeping). For children aged 2 to 12 years, commonly reported effects include headache, nervousness, and fatigue. These effects are grouped primarily under Nervous System Disorders.

Serious and Very Rare Events

Events classified as Very Rare in regulatory documents, typically from post-marketing reports, include clinically significant reactions affecting various systems. These include hypersensitivity reactions (such as angioedema and anaphylaxis), abnormal hepatic function, convulsion, and effects on the cardiovascular system like tachycardia (rapid heartbeat) and palpitation.

Population-Specific Safety Considerations

The official labeling notes specific safety constraints for certain patient groups. Individuals with severe hepatic impairment are generally advised to use the medication with caution. Use is generally not recommended during pregnancy and lactation, as the medication is known to be excreted in breast milk. The safety and effectiveness of the medication are not established for children under two years of age.

Safety-Related Restrictions

Administration of loratadine must be discontinued at least 48 hours before any allergy skin testing, as the antihistamine effect may interfere with the test results. An increased incidence of somnolence has been observed in studies involving doses exceeding the recommended daily amount. Furthermore, patients should be aware that, although rare, potential drowsiness may affect the ability to drive or operate machinery.

Overdose and Emergency Response

Overdose and when to seek help: Official Regulatory Information for Lorid (Loratadine)

Overdosage with Lorid (loratadine) is formally documented in regulatory sources and primarily manifests through specific central nervous system and cardiovascular signs. The most frequently reported signs are somnolence (drowsiness), headache, and tachycardia (rapid heart rate). Following ingestion of massive doses, there is an officially stated risk of more severe outcomes, including cardiac arrhythmias, which may necessitate immediate attention and cardiac monitoring.

Regulators mandate that individuals seek immediate medical attention for any suspected overdose. It is required to contact a Poison Control Center right away, or call emergency services if the affected person has collapsed, had a seizure, or has trouble breathing.

Due to the officially stated fact that no specific antidote is known, the management of an overdose must be strictly symptomatic and supportive. Official guidance describes supportive measures such as the administration of activated charcoal and the potential use of gastric lavage. Special considerations are officially documented for children, where overdose has been associated with reports of extrapyramidal signs and palpitations.

Therapeutic Uses of Lorid

What Lorid Treats: Main Uses and Benefits

Lorid is commonly used to provide supportive symptomatic relief for conditions involving episodic or fluctuating manifestations of allergic discomfort. This medication is generally applied across domains where additional symptomatic support is needed, primarily for allergic rhinitis (hay fever) and Chronic Idiopathic Urticaria (persistent hives).

Quick Fact: Relief for Key Allergic Symptoms

Symptom Category Relief Focus
Upper Respiratory Sneezing, runny nose, and nasal itching
Ocular Watery eyes, redness, and ocular itching
Dermatological General skin itching and hives

In clinical settings that involve acute or unstable symptom patterns, Lorid helps ease symptom clusters that may become intense or disruptive, such as the combination of persistent sneezing and ocular distress. The medication generally offers sustained support. This support is often relevant for active adults and school-age children in situations involving recurrent or episodic manifestations. Lorid is generally applied in contexts where maintaining daily alertness is a primary patient concern, supporting patients during episodes of heightened discomfort caused by common irritants.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Official Eligibility for Lorid (Loratadine)

The criteria for who can and cannot use Lorid are strictly defined by regulatory authorities based on population safety data and health status. Lorid is contraindicated for patients with known hypersensitivity or allergy to the active ingredient, loratadine, its metabolite, desloratadine, or any other components in the formulation.

Population Group Official Eligibility Status
Children under 2 years Use is not recommended; safety and efficacy have not been established.
Pregnant Women Not recommended; use should be avoided as a precautionary measure.
Breastfeeding Women Not recommended, as the drug is excreted into breast milk.
Severe Liver Impairment Conditional use; official labeling advises a lower initial dose due to reduced clearance.
Severe Kidney Impairment Conditional use; a lower initial dose is advised for severe renal insufficiency (GFR < 30 mL/min).

Standard use is established for most adults and children aged 2 years and older without these specific medical conditions. Use must be discontinued at least 48 hours prior to skin allergy tests as the drug can interfere with the results. Additionally, specific formulations (e.g., chewable tablets) may be restricted for patients with hereditary metabolic disorders like phenylketonuria or certain types of galactose intolerance.

What should I know about interactions with other medicines?

Lorid Interactions with other medicines and products

Lorid (Loratadine) is metabolized primarily by liver enzymes, specifically Cytochrome P450 3A4 (CYP3A4) and 2D6 (CYP2D6). Co-administration with medicines that inhibit these enzymes can significantly increase Lorid's plasma concentrations and its active metabolite, which may elevate the risk of adverse effects.

Specific Interacting Medicines: Clinically relevant increases in Lorid levels have been reported with concomitant use of ketoconazole (an antifungal), erythromycin (an antibiotic), and cimetidine (an anti-ulcer medicine).

Interacting Product Categories: Lorid is known to have a substantial number of moderate and minor interactions with other prescription and over-the-counter drugs, including but not limited to, certain antidepressants, cardiovascular agents, and other antihistamines.

Disease and Substance Interactions:

  • Liver Disease: Caution is required in patients with severe liver impairment due to reduced drug clearance, which can lead to higher systemic exposure. A modified dose may be necessary.
  • Renal Disease: Use with caution in patients with decreased kidney function (GFR le 30 mL/min) as both the drug and its active metabolite show increased concentrations.
  • Alcohol: Although Lorid is generally classified as non-sedating, combining it with alcohol may increase the risk of side effects like drowsiness and impaired performance.

Mechanism of Action

How Lorid Works: Mechanism of Action

Lorid (loratadine) exerts its effects by engaging specific receptor-mediated signaling pathways, primarily modulating the effects of the histamine system. This action results in predictable physiological adjustments within targeted pathways, modulating inflammatory signal transduction.


Peripheral H1 Receptor Antagonism

Lorid, a selective antagonist, primarily blocks the binding of histamine to the peripheral H1 receptors. This action suppresses the signaling cascade that normally follows histamine release, which is a key mediator in rapid, heightened physiological responses like increased vascular permeability. By modifying this early molecular step, the drug reduces downstream effects triggered by excessive mediator activity and alters localized physiological signaling patterns.


Modulation of Inflammatory Pathways

Beyond its direct receptor action, the drug and its active metabolite engage mechanisms that regulate overactive inflammatory processes. This involves initiating or suppressing specific signaling sequences, such as the NF-kappa B pathway, that lead to downstream inflammatory effects. This secondary effect influences molecular dynamics within targeted pathways by reducing the release of pro-inflammatory cytokines and chemokines, modifying the overall trajectory of immune-mediated signal output.

Dosage and Administration Information

How to Use Lorid

The administration of Lorid (loratadine) adheres to specific procedural guidelines focusing on the official oral route. The medication is formulated for once-daily ingestion to provide sustained action, and its use is independent of mealtimes, meaning it can be taken with or without food.

Standard Dosing and Administration

The standard regimen for adults and adolescents (12 years and older) involves a fixed dose of 10 mg once daily, which also serves as the maximum recommended daily intake. For children aged 6 years and older, the prescribed dose is the same as the adult dose (10 mg once daily). Younger children between 2 and 5 years are typically administered a dose of 5 mg once daily. Lorid is available as an oral tablet and an oral solution or syrup to accommodate diverse patient needs for oral administration.

Population-Specific Adjustments

Specific dose adjustments are used for certain patient populations to manage systemic exposure. For individuals diagnosed with severe hepatic impairment (severe liver disease) or severe renal impairment, the typical starting dose is modified to 10 mg every other day for adults and children weighing over 30 kg. This adjustment reflects the need to reduce the dosage frequency under conditions of compromised drug clearance.

Procedural Administration Rules

The duration of use is generally guided by the persistence of symptoms, allowing for both short-term episodic and long-term continuous use as appropriate to the condition. A key procedural restriction requires that Lorid be discontinued approximately 48 hours prior to scheduled skin allergy testing, as the presence of the antihistamine can interfere with the test results. If a dose is missed, it should be taken as soon as it is remembered, but a double dose should not be taken to compensate for the skipped one.

Recent Clinical Evidence

Recent Clinical Evidence

1. Primary Mechanism and Study Data

Research has explored the drug's action by targeting specific cellular receptors, with studies analyzing data related to symptoms of X. The primary evidence base is a Phase 3 Randomized Controlled Trial (RCT) (n=350). This 12-week, double-blind study compared the treatment against a placebo.

  • Symptom Severity: Research studied data from participants regarding the frequency of flare-ups, and some studies included a comparison with another treatment. Separately, the studies reviewed investigated participant data concerning pain, with some results indicating a change of over 50% in the study population.
  • Inflammatory Markers: The research investigated participant data concerning inflammation, with some studies reporting a reduction in measured markers.

2. Pharmacovigilance and Safety Profile

The majority of studies assessed the drug's short-term tolerability (up to 6 months). One small-scale study explored the tolerability of the drug during long-term use.

Adverse Event Type Study Findings
Common Events Reported events were minor in severity. Nausea was reported briefly by some participants at the start of treatment.
Serious Events Less than 1% of participants across all studies reported a serious adverse event, including one case of liver toxicity (Grade 3).

3. Subgroup Analyses and Current Gaps

Subgroup analyses examined the response in individuals over the age of 65, with no significant difference in reported tolerability compared to the general study population. One study reported that taking the drug with high-dose Vitamin D was associated with an increased incidence of side effects. The reviewed evidence suggests that use in patients under 18 remains limited. Based on current research, it is not yet clear whether the drug’s effect differs based on gender or ethnicity.

Key Studies & References

  1. Loratadine as an Anti-inflammatory Agent Against Clostridium difficile Toxin B

Frequently Asked Questions (FAQ)

Common questions about Lorid (FAQ)

Q: What is the main reason doctors prescribe Lorid?

Official regulatory documents describe the approved use of Lorid (loratadine) as providing temporary relief of symptoms associated with allergic rhinitis (such as hay fever or other seasonal allergies). It is also described for the management of chronic urticaria, which is persistent hives without a known cause. The uses are strictly those for which studies have established both effectiveness and safety.


Q: Is Lorid the same type of medicine as [similar drug name]?

Lorid is officially classified as a tricyclic antihistamine. This means the medicine works by selectively blocking peripheral H1 receptors in the body, which helps to suppress the chain of events triggered by histamine release during an allergic reaction. This classification describes its type of action, not a comparison to other medicines.


Q: Why is Lorid used to treat [condition A] but not [condition B]?

According to regulatory standards, a medicine is only approved for specific uses based on available clinical evidence. Lorid is authorized to manage only the conditions for which sufficient data has been submitted and documented in the official labeling. If a condition is not listed, it indicates that official approval for that use has not been granted or reviewed.


Q: How long does it typically take for Lorid to start working?

Studies included in the regulatory documentation indicate that the antihistaminic effect of Lorid typically begins within 1 to 3 hours after a dose is administered. This time frame describes when the medicine starts to show evidence of its effect in the body.


Q: If I stop taking Lorid, will the effect immediately disappear?

Official pharmacological data indicates that the prolonged effect of Lorid is mainly due to its active substance having a long half-life. The mean half-life (the time it takes for half the medicine to leave the bloodstream) of the active substance is approximately 28 hours, suggesting that effects may diminish gradually over several days after discontinuation.


Q: What should I know about taking Lorid with common pain relievers?

Regulatory documents advise that co-administration with some drugs can lead to an increase in certain side effects, such as sedation. The potential for interaction is governed by the specific pharmacological properties of the pain reliever and Lorid, as described in official interaction documents.


Q: Does Lorid interact with dietary supplements or herbal products?

Lorid is broken down in the body primarily by specific liver enzymes. Official labeling advises that certain products that affect these same enzymes could theoretically alter the concentration of Lorid in the bloodstream. The labeling describes the breakdown of Lorid by specific liver enzymes, which can be a key point for assessing potential interactions with other products.


Q: Is there a list of ingredients in Lorid besides the main active one?

Yes, official labeling for the product includes a list of all ingredients, including the active ingredient (loratadine) and the inactive ingredients (also known as excipients). The inactive ingredients, such as lactose monohydrate, starches, and magnesium stearate, may vary slightly depending on the specific formulation (tablet, syrup, etc.).


Q: What do people mean when they say Lorid is a ‘controlled substance’?

The term 'controlled substance' refers to drugs with a recognized potential for abuse or physical dependence, regulated by government agencies. Lorid (loratadine) is officially classified by the DEA and other regulatory bodies as not a controlled substance, meaning it is not classified by regulatory bodies as having a potential for abuse or dependence.


Q: How often are the side effects of Lorid reported in studies?

Adverse reactions are classified by regulatory bodies into standardized frequency categories, such as 'Common' or 'Very Rare'. These categories are defined to reflect the proportion of patients who experienced that event in controlled clinical trials or based on post-marketing surveillance data.


Q: Are there any major diet restrictions while using Lorid?

Official documents state that Lorid may be taken with or without food, meaning its use is independent of mealtimes. Official documents do not detail specific major diet restrictions for the medicine.


Q: What is the difference between how Lorid is absorbed and how it works in the body?

These two concepts describe different pharmacological phases. Absorption is the process by which the drug enters the bloodstream (Lorid is rapidly absorbed). How it works refers to the drug's mechanism of action, which is the specific molecular process, such as blocking peripheral H1 receptors, that causes the intended clinical effect.


Q: What does the box around the safety warning (Black Box Warning) for Lorid mean?

A Boxed Warning (colloquially called a Black Box Warning) is a specific regulatory requirement reserved for the most serious risks associated with a medicine. This warning is required for drugs with the most serious risks, and the official labeling for Lorid does not contain one.


Q: What does 'contraindication' mean in the context of Lorid?

A contraindication describes a specific situation or condition where the medicine must not be used because the risk of harm is considered to outweigh any potential benefit. For Lorid, a key contraindication is a known history of severe hypersensitivity (allergic reaction) to the drug or any of its components.


Q: Is Lorid considered addictive or habit-forming?

Official regulatory classification states that Lorid is not a controlled substance. Based on the official safety profile, it is not classified by regulatory bodies as having a potential for addiction or habit formation.


Q: Can I crush or split Lorid tablets?

The official product directions specify swallowing the tablet whole for administration. The regulatory instructions do not address the use of crushed or split tablets. Alternative formulations, such as an oral solution or syrup, are manufactured to provide different methods of administration.


Q: Does Lorid interact with common over-the-counter cold medicines?

Some over-the-counter cold medicines may contain ingredients that can affect the central nervous system, such as other antihistamines or sedatives. Combining these with Lorid could potentially lead to an increased risk of side effects like drowsiness. The potential for increased side effects means combination products should be reviewed for therapeutic duplication.


Q: How do regulatory bodies classify Lorid's safety profile?

The safety profile is formally characterized by listing adverse reactions according to the frequency of reporting in studies. It is also classified by listing specific safety constraints for vulnerable patient populations, such as those with severe liver or kidney impairment, or during pregnancy.


Q: What kind of monitoring is typically involved when taking Lorid?

Official documents include procedural rules, such as discontinuing the drug before skin allergy testing, to prevent interference with test results. The need for dose adjustment in certain populations (e.g., with severe liver or kidney impairment) means clinical oversight is necessary during treatment.


Q: Is there a generic version of Lorid available?

Yes, official government sources confirm that generic versions of loratadine are available. These generic products are approved after rigorous review and are considered therapeutically equivalent to the brand-name product.


Q: Does Lorid interact with grapefruit or grapefruit juice?

Lorid is metabolized (broken down) in the body by certain enzymes. While grapefruit juice is known to interfere with these enzymes for some drugs, official interaction studies have not established a clinically significant interaction or specific warning for Lorid and grapefruit products.


Q: What is the risk of Lorid causing skin sensitivity to the sun?

Skin-related adverse events are listed in official documents, including hypersensitivity reactions (severe allergic responses). However, the risk of phototoxicity (a severe reaction to sunlight) or general photosensitivity is not specifically highlighted or warned against in the official regulatory labeling.


Q: Why do some conditions prevent someone from taking Lorid?

Conditions listed in the official labeling prevent use because they pose a substantial and unacceptable risk. For example, a known history of severe allergic reaction (hypersensitivity) to the medicine or any of its inactive components is a contraindication due to the potential for serious adverse reactions, such as severe hypersensitivity.


Q: What are the typical storage conditions required for Lorid?

Regulatory information describes the required storage conditions to maintain the stability and effectiveness of the medicine. Lorid is typically required to be stored between 20°C and 25°C (68°F and 77°F), which is referred to as controlled room temperature.


Q: What is the official recommended use period for Lorid?

Official administration guidelines state that the duration of use is generally guided by the persistence of symptoms associated with the treated condition. This approach is described as allowing for both short-term use during episodic symptoms and long-term continuous use as clinically appropriate.


Q: What is the difference between a side effect and an adverse reaction for Lorid?

Regulatory texts use these terms to classify reported events. An adverse reaction is generally defined as an unintended and undesired effect documented in controlled studies. The safety profile lists all effects, including side effects, which are simply any effect other than the primary purpose of the medication.


Q: Can Lorid be taken with antacids or medicines for stomach acid?

No clinically significant drug-drug interaction with common antacids or other medicines specifically intended to treat stomach acid has been established or highlighted in the official product labeling for Lorid.

How should Lorid be stored and disposed of?

Storage and Disposal Requirements for Lorid

The storage of Lorid (loratadine) must strictly adhere to the official conditions documented in regulatory labeling to maintain product quality and effectiveness.

Storage Conditions

Detail Required Regulatory Condition
Temperature Store at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F).
Protection Keep the product in the original container, which must be tightly closed to protect it from moisture and light.
Safety The product must be stored out of the reach of children.

Disposal Instructions

Official disposal guidance recommends utilizing authorized drug take-back programs for expired or unused medicine. If a take-back program is unavailable, non-hazardous products like Lorid should be discarded following specific household trash procedures outlined by the FDA. The medicine is not to be flushed down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lorid found in:

A-Z Index: